CP and breast carcinoma: NCI tested 60 cell lines originating from nine cancer cell lines, including colon, melanoma, leukemia, lung, prostate, CNS, ovarian, renal, and breast cancer cell lines, for the multitarget anticancer efficacy of the newly synthesized CP derivative.